NICE Review Flags Research Gaps in Psoriasis Care and Treatment Risks
A NICE guideline review identified research gaps in psoriasis assessment and management, including severity scoring, methotrexate liver risks, early systemic treatment, self-management programs, and long-term topical therapy. Current assessment tools lack validation in non-specialist settings, pediatric groups, and patient-reported and remote monitoring measures. Concerns about methotrexate-related liver disease often lead patients to stop treatment early, and more robust studies are needed.
A NICE review points to unanswered questions across psoriasis care. It highlights weak validation of severity measures outside specialist clinics, in children, and for patient-reported or remote-monitoring tools. The review also calls for better data on how skin symptoms and joint disease overlap in psoriatic arthritis.
Concerns about methotrexate-related liver injury often prompt patients to stop treatment early, yet existing studies may not fully account for obesity, diabetes, or alcohol use. The review also seeks evidence on early systemic therapy, structured self-management support, and long-term topical corticosteroid risks such as skin thinning and systemic absorption.
The review could influence how clinicians and health systems prioritize psoriasis research and care. Patients may benefit if clearer severity tools and safer treatment guidance reduce uncertainty, especially those in primary care, children, and people weighing methotrexate. Better evidence on early systemic therapy and self-management could shape expectations and resource use, though any changes would depend on further studies and implementation.